Stability of Borna disease virus-based episomal vector under physical and chemical stimulation.
animal RNA virus
vaccines and antiviral agents
viral vector
virology
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
31
08
2021
received:
07
06
2021
accepted:
27
09
2021
pubmed:
8
10
2021
medline:
11
1
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Borna disease virus (BoDV), a nonsegmented, negative-sense RNA virus, establishes persistent infection and replicates in the cell nucleus. Since BoDV genomic RNA exists as episomal RNA, the host genome is not invaded by BoDV infection. These unique features make BoDV a promising gene delivery system as an RNA virus-based episomal vector (REVec). Previously, the stable expression of genes of interest in vitro and in vivo using a REVec was reported. For the clinical application of a REVec, the fundamental properties under various physical and chemical conditions must be determined to develop purification processes, supply chains, and biosafety management. This study investigated the effects of the following conditions on the inducibility of transmission-defective ΔG-REVec: freeze-thaw cycles, dehydration, UV, temperature, pH, and reagents for virucides and laboratory experiments. Although the titer of ΔG-REVec was not influenced by the freeze-thaw process or 5 minute incubation at ≤50°C, ΔG-REVec was significantly inactivated by incubation at ≥70°C for 5 minutes. The induction titer of ΔG-REVec was decreased by long-term incubation, dehydration, and UV irradiation in a temperature- and time-dependent manner. ΔG-REVec was sensitive to lower pH and inactivated by chemical reagents under general conditions. These results provide important knowledge for developing the clinical use of REVec and biosafety management.
Identifiants
pubmed: 34617609
doi: 10.1111/1348-0421.12946
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24-30Subventions
Organisme : Kyoto University
ID : the Joint Usage/Research Center Program on inFront
Organisme : Japan Agency for Medical Research and Development
ID : JP20wm0325011h0001
Organisme : Japan Agency for Medical Research and Development
ID : JP19fm0208014
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : JP16H06429
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : JP16K21723
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : JP16H06430
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : JP19H04834
Organisme : Japan Society for the Promotion of Science
ID : Core-to-core program
Organisme : Japan Society for the Promotion of Science
ID : JP18K05991
Organisme : Japan Society for the Promotion of Science
ID : JP19K22530
Organisme : Japan Society for the Promotion of Science
ID : JP20H00662
Organisme : JSPS KAKENHI
ID : JP20H00662
Organisme : JSPS KAKENHI
ID : JP19K22530
Organisme : JSPS KAKENHI
ID : JP18K05991
Organisme : MEXT KAKENHI
ID : JP16H06429
Organisme : MEXT KAKENHI
ID : JP16K21723
Organisme : MEXT KAKENHI
ID : JP16H06430
Organisme : MEXT KAKENHI
ID : JP19H04834
Organisme : JSPS Core-to-Core Program, AMED
ID : JP19fm0208014
Organisme : JSPS Core-to-Core Program, AMED
ID : JP20wm0325011h0001
Organisme : Joint Usage/Research Center Program on inFront, Kyoto University
Informations de copyright
© 2021 The Societies and John Wiley & Sons Australia, Ltd.
Références
Briese T, de la Torre JC, Lewis A, Ludwig H, Lipkin WI. Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A. 1992;89:11486-9. https://doi.org/10.1073/pnas.89.23.11486
Ludwig H, Bode L, Gosztonyi G. Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol. 1988;35:107-15.
Ludwig H, Bode L. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev Sci Tech l'OIE. 2016;19:259-88. https://doi.org/10.20506/rst.19.1.1217
Briese T, Schneemann A, Lewis AJ, et al. Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A. 1994;91:4362-6.
Honda T, Tomonaga K. Nucleocytoplasmic shuttling of viral proteins in Borna disease virus infection. Viruses. 2013;5:1978-90. https://doi.org/10.3390/v5081978
Hock M, Kraus I, Schoehn G, et al. RNA induced polymerization of the Borna disease virus nucleoprotein. Virology. 2010;397:64-72. https://doi.org/10.1016/j.virol.2009.11.016
Watanabe Y, Ohtaki N, Hayashi Y, Ikuta K, Tomonaga K. Autogenous translational regulation of the Borna disease virus negative control factor X from polycistronic mRNA using host RNA helicases. PLoS Pathog. 2009;5:e1000654. https://doi.org/10.1371/journal.ppat.1000654
Lennartz F, Bayer K, Czerwonka N, et al. Surface glycoprotein of Borna disease virus mediates virus spread from cell to cell. Cell Microbiol. 2016;18:340-54. https://doi.org/10.1111/cmi.12515
Matsumoto Y, Hayashi Y, Omori H, et al. Bornavirus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. Cell Host Microbe. 2012;11:492-503. https://doi.org/10.1016/j.chom.2012.04.009
Daito T, Fujino K, Honda T, Matsumoto Y, Watanabe Y, Tomonaga K. A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. J Virol. 2011;85:12170-8. https://doi.org/10.1128/JVI.05554-11
Fujino K, Yamamoto Y, Daito T, Makino A, Honda T, Tomonaga K. Generation of a non-transmissive Borna disease virus vector lacking both matrix and glycoprotein genes. Microbiol Immunol. 2017;61:380-6. https://doi.org/10.1111/1348-0421.12505
Sakai M, Ueda S, Daito T, et al. Degradation of amyloid β peptide by neprilysin expressed from Borna disease virus vector. Microbiol Immunol. 2018;62:467-72. https://doi.org/10.1111/1348-0421.12602
Komatsu Y, Takeuchi D, Tokunaga T, et al. RNA virus-based episomal vector with a fail-safe switch facilitating efficient genetic modification and differentiation of iPSCs. Mol Ther Methods Clin Dev. 2019;14:47-55. https://doi.org/10.1016/j.omtm.2019.05.010
Komatsu Y, Tanaka C, Komorizono R, Tomonaga K. In vivo biodistribution analysis of transmission competent and defective RNA virus-based episomal vector. Sci Rep. 2020;10:1-12. https://doi.org/10.1038/s41598-020-62630-7
Danner K, Heubeck D, Mayr A. In vitro studies on Borna virus - I. The use of cell cultures for the demonstration, titration and production of Borna virus. Arch Virol. 1978;57:63-75. https://doi.org/10.1007/BF01315638
Qiao Z, Ye Y, Chang PH, Thirunarayanan D, Wigginton KR. Nucleic acid photolysis by UV254 and the impact of virus encapsidation. Environ Sci Technol. 2018;52:10408-15. https://doi.org/10.1021/acs.est.8b02308
Zimmer B, Summermatter K, Zimmer G. Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus. Vet Microbiol. 2013;162:78-84. https://doi.org/10.1016/j.vetmic.2012.08.023
De Benedictis P, Beato MS, Capua I. Inactivation of avian influenza viruses by chemical agents and physical conditions: a review. Zoonoses Public Health. 2007;54:51-68. https://doi.org/10.1111/j.1863-2378.2007.01029.x
Haddock E, Feldmann F, Feldmann H. Effective chemical inactivation of Ebola virus. Emerg Infect Dis. 2016;22:1292-4. https://doi.org/10.3201/eid2207.160233
Zimmermann W, Breter H, Rudolph M, Ludwig H. Borna disease virus: immunoelectron microscopic characterization of cell-free virus and further information about the genome. J Virol. 1994;68:6755-8. https://doi.org/10.1128/jvi.68.10.6755-6758.1994
Danner K, Mayr A. In vitro studies on Borna virus. II. Properties of the virus. Arch Virol. 1999;144:261-71.
Howard DB, Harvey BK. Assaying the stability and inactivation of AAV serotype 1 vectors. Hum Gene Ther Methods. 2017;28:39-48. https://doi.org/10.1089/hgtb.2016.180
Gruntman AM, Su L, Su Q, Gao G, Mueller C, Flotte TR. Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods. 2015;26:71-6. https://doi.org/10.1089/hgtb.2015.040
Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 2001;8:1281-90. https://doi.org/10.1038/sj.gt.3301527